Showing 971-980 of 3030 results for "".
Great Expectations
https://practicaldermatology.com/topics/practice-management/great-expectations/20607/A look ahead to hot topics at Cosmetic Surgery Forum 2017Neurotoxin Tips for Beginners and Advanced Users
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/neurotoxin-tips-for-beginners-and-advanced-users/21578/Experts from the international aesthetics arena share pearls for maximizing neurotoxins.DermWireTV: Epsolay Approval; See My Skin from Vaseline; Jori Launch; Novartis Grant for Farmworker Justice
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-epsolay-approval-see-my-skin-from-vaseline-jori-launch-novartis-grant-for-farmworker-justice/20094/Vaseline’s new See My Skin Campaign aims to help consumers of all skin types recognize skin diseases and connect them with dermatologists who can help manage them. Uchenna Okereke, MD discusses the initiative. Farmworker Justice, an organization dedicated to empowering farmworkers to improve immigraPsoriasis Wish List
https://practicaldermatology.com/topics/psoriasis/psoriasis-wish-list/20667/Clinical thought leaders share what they hope for to improve treatment in the future.Hyperpigmentation Treatment Pearls and More
https://practicaldermatology.com/conferences/cosmetic-surgery-forum-2022/hyperpigmentation-treatment-pearls-and-more/20161/Corey Hartman, MD shares his approach to treating periorbital hyperpigmentation in darker skin types, including using fillers to replace volume, give lift, and replace loss of bony structures and fat pads. Dr. Hartman also discusses the benefits of Cynosure’s PicoSure device to correct hyperpigmentaDermWireTV: Incyte's Opzelura, BMS Patient Week, Science of Skincare Summit
https://practicaldermatology.com/topics/psoriasis/dermwiretv-incytes-opzelura-bms-patient-week-science-of-skincare-summit/20003/Incyte’s Opzelura is the first topical JAK inhibitor approved in the US. Lawrence Eichenfield, MD weighs in on the cream formulation of ruxolitinib for treatment of mild-to-moderate atopic dermatitis in non-immunocompromised patients 12 years of age and older. Bristol Myers Squibb's seventh Global PSkin Reactions: Understanding New Drug Adverse Effects
https://practicaldermatology.com/conferences/aad-summer-2021/skin-reactions-understanding-new-drug-adverse-effects/19975/In addition to needing to stay abreast of new drugs in dermatology, it's important for dermatologists to stay informed about new medications that come to market in general. Vinod Nambudiri, MD, MBA says there are often dermatology-related adverse events that need to be managed. He discusses new cancUpdates on AD Therapeutics
https://practicaldermatology.com/topics/atopic-dermatitis/updates-on-ad-therapeutics/19760/It's a "super-exciting" time in the world of atopic dermatitis because of a number of new developments happening very rapidly, shares Peter Lio, MD. Recent approvals and additional indications for treatments like dupilumab and crisaborole in pediatric populations have been welcome additions. And theBespoke for Bros: A Different Approach for Male Patients
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/bespoke-for-bros-a-different-approach-for-male-patients-/19561/Physical features aside, there may be important differences in how male patients think about and approach cosmetic concerns. According to Heidi Waldorf, MD, while women tend to seek a youthful appearance, men often want to appear as though they have not aged—and stopping the aging clock requires a fIdentifying SCC Risk
https://practicaldermatology.com/topics/skin-cancer-photoprotection/identifying-scc-risk/20144/Sherrif Ibrahim, MD discusses the challenges of managing squamous cell carcinoma (SCC). Great steps have been made in clinical, pathological staging systems, but Dr. Ibrahim says it’s still difficult to determine what to do with borderline cases. He talks about the need to determine frequency and in